Healthcare Industry News: Symphony
News Release - March 14, 2006
Symphony Medical Licenses NDI Medical Product for Heart TreatmentMedical device makers partner to treat atrial fibrillation
CLEVELAND, March 14 (HSMN NewsFeed) -- Symphony Medical, Inc. has entered an exclusive agreement to use NDI Medical, Inc.'s proprietary neurostimulation technology, Checkpoint AF(TM), in its first product for the treatment of post- operative Atrial Fibrillation (AF).
This unique approach to the treatment of post-operative AF is a coupling of NDI Medical's neurostimulation diagnostics to identify target nerve centers on the heart with Symphony Medical's proprietary biopolymer therapy and delivery system. This therapy may lead to a breakthrough treatment of atrial fibrillation, which often occurs following open heart surgery.
Post-operative AF occurs in approximately 25-30% of all patients undergoing a Coronary Artery Bypass Graft (CABG) procedure and approximately 80% of patients that have a valve procedure. Post operative AF slows patient recovery and can lead to blood clots and long-term AF. Human clinical trials using this treatment are currently underway.
"We custom designed the Checkpoint AF to be used on the most important muscle of all, the heart," said Geoffrey Thrope, President and CEO of NDI Medical. "The Checkpoint AF is another example of how NDI Medical's leadership in neurostimulation is helping companies accelerate the development of their medical treatments and products."
"Our goal is to avoid the serious effects of atrial fibrillation with new innovative treatments, and NDI Medical is helping us get them to the patient sooner," said Mark Maciejewski, Symphony's President and CEO.
About Symphony Medical, Inc.
A Cleveland Clinic spin-off company, Symphony Medical recently raised more than $6 million in equity funding to develop treatments for atrial fibrillation and other ailments. Symphony Medical was founded in 2002 with technologies that focus on the development and commercialization of novel treatments of cardiovascular conduction abnormalities. Using practical and cost-effective approaches, Symphony's products are designed to correct cardiac conduction disorders through safe biologic, non-ablative means. Presently, Symphony is engaged in the clinical development phase of its first product for the prevention of post-operative atrial fibrillation. Moving forward, Symphony expects to commercialize this and other products through corporate partners with global marketing and sales capabilities. Through its investors, advisors and management, the company has established a culture of rapid product development, continuous expansion of intellectual property, minimization of capital and personnel expenses, and superior science and clinical know-how.
About NDI Medical, Inc.
Founded in 2002, NDI Medical is a leader in the development and manufacture of cardiac and neurostimulation medical devices. The company's flagship product, the Micropulse IPG, is the smallest available two-channel, rechargeable IPG, which can be customized and scaled to achieve the therapeutic objectives of its partners. NDI Medical has an experienced team of business executives, engineers and regulatory professionals who work with companies and researchers to accelerate and enhance the commercialization of promising neurostimulation products. NDI Medical is headquartered in the eastern suburbs of Cleveland, Ohio.
Source: NDI Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.